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ABSTRACT
According to Bian et al., polymorphonuclear leukocytes (PMN) undergo
phenotypic changes, suggestive of bone marrow (BM) myeloid reprogramming,
under chronic inflammatory conditions 1 . Utilizing a murine dextran sodium
sulfate (DSS)-induced colitis-to-recovery model, we characterized the BM
myeloid compartment during acute, post-acute/chronic, and resolution of
inflammation. Percoll density gradient separation of BM leukocytes from colitisto-recovery mice revealed significant expansion of the immature myeloid
compartment (IMC) beginning at the post-acute stage and extending until after
complete inflammation resolution. Additionally, we show that both the mature
PMN and immature myeloid populations increased production of reactive

oxygen species (ROS) and demonstrated enhanced infiltration during zymosaninduced peritonitis. Interestingly, the expanded immature granulocytes not only
expressed CXCR2 and ARG-1, but also demonstrated potent inhibition of T cell
proliferation. These findings suggest that the myeloid compartment undergoes
reprogramming at the post-acute phase producing functionally primed PMN that
accelerate pathogen clearance, as well as immature Ly6G + CXCR2 high
immunosuppressive effector cells that likely play a role in inflammation recovery
and tissue repair. Our study could provide novel strategies for treatment of
chronic inflammatory diseases such as ulcerative colitis.

INDEX WORDS: Leukocyte response, PMN, MDSC, Inflammation, Tissue
recovery, Colitis
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1
1.1

INTRODUCTION

Dissertation Introduction

Acute inflammation is the immediate biological response to injury, infection,
and trauma. At the site of inflammation, infected tissue resident and damaged
epithelial/endothelial cells secrete a variety of soluble factors, such as
interleukin (IL)-1b,IL-6, IL-17, IL-8 etc., required to initiate and perpetuate
inflammation

1-5 .

Although, this process involves multiple steps and several cell

types, leukocytes are found to be crucial for regulation of inflammatory
responses. Specifically, leukocyte proliferation, differentiation, adhesion,
migration, and effector functions are required for onset and resolution of acute
inflammation

3,5,6 .

In acute inflammation, the goal of these processes is to rapidly remove the
extracellular insult, suppress the immune response, and allow for tissue repair
and return to homeostasis. However, when the insult persists inflammation
cannot be resolved, resulting in continuous leukocyte infiltration and/or
functional dysregulation. Hence, leukocytes act as a double-edged sword,
promoting development of autoimmune and chronic inflammatory disorders like
inflammatory bowel disease (IBD), arthritis, and cancer

7-9 .

Furthermore,

understanding how leukocytes are dynamically regulated during both acute and
chronic inflammation can provide novel therapeutic strategies for the prevention
and control of these diseases.

2

1.2 Background
1.2.1 Polymorphonuclear leukocyte mediated acute inflammation
In healthy individuals, Ly6G hi Ly6C + polymorphonuclear leukocytes (PMN)
comprise ~50-60% of total circulating leukocytes, with an average of 1.5 x 10 11
leukocytes being generated in the bone marrow (BM) per day

4,6 .

PMN that are

generated in the BM express high levels of chemokine receptor CXCR2 on their
surfaces. Expression of CXCR2 allows rapid mobilization of PMN in circulation
under inflammatory conditions, making them the first leukocytes to infiltrate
the site of inflammation

1,10-12 .

Once in circulation, PMN use chemotaxis to

navigate a chemokine gradient of C-X-C motif chemokine ligand 1 (CXCL1),
CXCL2, IL-8 and infiltrate the inflamed area. To accomplish this, they bind
selectins on the endothelial membrane with carbohydrate ligands on their
surface, which initiates PMN tethering, rolling, adhesion, and transmigration

13-

15 .

Infiltration of PMN is followed by rapid removal of pathogen, as they possess a
variety of killing mechanisms that work collaboratively to target extracellular
insults. These mechanisms include phagocytosis, reactive oxygen species (ROS)
production, degranulation, and neutrophil extracellular trap (NET) formation
6,16,17 .

However, while eliminating pathogens, PMN also damage tissues, thus

contributing to ongoing inflammation. After preforming their effector functions,
PMN undergo apoptosis and are cleared by macrophages. Uptake of apoptotic
PMN induces polarization of M2 macrophages, which are associated with antiinflammatory responses and tissue repair

4,18-21 .

Since PMN are the primary

3

leukocytes responsible for mediating acute inflammation and resolution their
infiltration and response must be tightly regulated.
1.2.1.1 PMN recruitment and infiltration
Several studies have shown that chemokine receptors 2 and 4 (CXCR2 & CXCR4)
mediate neutrophil retention and release from the BM into circulation

12,22 .

Binding of CXCR4 to its ligand CXCL12 negatively regulates neutrophil exit from
the BM by inducing secretion of retention factors. CXCL12 is constitutively
secreted by osteoblasts, vascular endothelial cells, stromal cells, and CXCL12abundant reticular cells (CAR) to sequester PMN in the BM at homeostasis

11,23 .

However, during inflammation, high expression of chemokines CXCL8 (IL-8),
CXCL1, and CXCL2 in the serum override CXCR4/CXCL12 signaling and
positively regulates neutrophil trafficking by upregulating and ligating CXCR2
12,24 .

Ligation of CXCR2 partially activates PMN, facilitates chemotaxis, and

increases expression of adhesion molecules needed for release into circulation
and migration into tissues

25,26 .

Once PMN are recruited into circulation, they

follow a chemotactic gradient to accumulate at the site of inflammation.

Circulating PMN are tethered to the endothelium by E-,L-, and P- selectins that
initiate PMN rolling by weakly binding and releasing carbohydrate ligands, such
as P-selectin glycoprotein ligand-1 (PSGL-1) on their surface

27-29 .

Rolling allows

PMN to detect chemokines bound to heparan sulfates on the endothelium. These
interactions activate PMN and promote firm adhesion to the endothelial
membrane

30,31 .

Specifically, CXCL1, CXCL2, CXCL8 have been shown to ligate

CXCR2 and induce expression of high-affinity integrin mediated binding
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through conformational changes in the LFA-1 or MAC-1 complexes. LFA-1 and
MAC1 bind ICAM1 and ICAM2, respectively, on the endothelium to firmly adhere
PMN

28,32-35 .

After adhesion, PMN crawl along the endothelium following a

chemotactic gradient to identify the preferred site of transmigration. Adhesion
junction molecules mediate PMN paracellular (at endothelial cell-cell junctions)
transmigration- it should however be noted that PMN can also transcellularly
(through an endothelial cell) migrate but prefer the former

13,14,36-39 .

1.2.1.2 PMN response and acute inflammation
After migrating to the inflamed area, PMN uptake and degrade
damaged/infected cells and extracellular pathogens by phagocytosis.
Phagocytosis further activates PMN, inducing degranulation, secretion of ROS,
and NET formation

40,41 .

The most notable characteristic of PMN is that they

possess azurophilic and specific granules comprised of various enzymes and
antimicrobial peptides required for pathogen killing, including myeloperoxidase
(MPO), neutrophil elastase (NE), and matrix metalloproteases (MMPs)

15,42-44 .

PMN activation also initiates generation of unstable oxygen radicals that react
with proteins, lipids, and DNA

45 .

The presence of ROS during inflammation has

been shown to play a role in PMN-mediated microbial killing. ROS also facilitate
PMN infiltration by disrupting the cell membrane and increasing mucosal
permeability. Under acute inflammatory conditions, tissues like the intestinal
mucosa use a protective system of antioxidants to counteract any potentially
harmful effects of ROS

45-48 .

Interestingly, ROS are also found to contribute to

PMN apoptosis and angiogenesis during inflammation resolution and tissue
regeneration, suggesting a role in the anti-inflammatory process

16,49 .

Similarly,
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NET formation has been implicated in both inflammation and resolution where
they were found to induce platelet adhesion, activation, and aggregation

17,50 .

Specifically, ligand binding of PMN Toll-like receptors (TLR) and Fc receptors
(FcR) initiates the NETosis process. NETs are web-like structures of chromatin
fibers that contain granular proteins such as NE, cathepsin G, and MPO.
Invading pathogens are trapped and immobilized/degraded in NETs before
being phagocytosed by PMN

51-53 .

PMN are required for the success of various pro-inflammatory and antiinflammatory processes that occur during acute inflammation. Proper clearance
of extracellular insults is dependent on the infiltration and effector functions of
these leucocytes. Furthermore, their apoptosis and clearance, ROS production,
and NET formation serve dual roles by mediating inflammation resolution, as
well as pathogen eradication. However, because PMN responses are extremely
potent, their dysregulation can promote development and progression of various
inflammatory diseases such as experimental autoimmune encephalomyelitis
(EAE), rheumatoid arthritis (RA), Crohn’s disease, and ulcerative colitis
1,5,7,43,54,55 .

Since PMN are required for host immune defense, they cannot be

completely inhibited. Thus, novel mechanisms are needed to precisely regulate
PMN infiltration and responses. This dissertation focuses on investigating the
mechanism of ulcerative colitis using a murine model.

6

1.2.2 Contribution of the PMN response to ulcerative colitis
development and progression
PMN have been implicated in the pathogenesis of multiple chronic inflammatory
diseases. In this study, we used a murine model of ulcerative colitis to
investigate the role of PMN infiltration and response under inflammatory
conditions. Colitis is classified as a multifaceted disease that can be attributed to
an overreactive immune response in the intestines, especially in the colon and
rectum

54,56-58 .

When the intestinal epithelium is damaged, PMN are recruited to

the site of inflammation where their primary purpose is to eliminate the insult.

While the causes of colitis are not well understood, research suggests that a
combination of genetic susceptibility, immune system dysregulation, and
microenvironmental factors contribute to an inability to adequately clear the
insult

4,56,59-61 .

Failure to remove the extracellular insult results in significantly

increased proinflammatory cytokine expression and continuous infiltration of
neutrophils, macrophages, and lymphocytes into the mucosa. Massive migration
into the inflamed colon causes substantial tissue damage and interrupts the
tissue regeneration program

57,62-65 .

Due to this, functionality of the colon and

rectum can often become impaired, thus promoting the development of
symptoms such as diarrhea, weight loss, abdominal pain, and rectal bleeding
58,66 .

Multiple studies have shown a significant correlation between PMN
accumulation in the colon and disease severity in individuals with colitis.

7

Specifically, it was documented that large numbers of infiltrating PMN damage
epithelial junction proteins needed for membrane integrity, such as β-catenin,
E-cadherin, and junction adhesion molecule (JAM)-A. Damaging these proteins
creates gaps in the endothelium that further promote PMN infiltration and
facilitate translocation of microbiota, thereby perpetuating the chronic
inflammatory conditions

7,67-69 .

In addition to their infiltration/accumulation in

tissues, PMN responses exhibit a deleterious effect at the site of inflammation.
1.2.2.1 Regulation of PMN responses during colitis
Although PMN pathogen killing functions are crucial for host immune defense,
they are major contributors to colitis disease progression. During post-acute
colitis PMN display enhanced phagocytosis, which makes them efficient at
removing extracellular insult. PMN accumulation and increased lifespan in
tissues under these conditions also leads to a concomitant reduction in apoptosis
55,70-73 .

These findings suggest that despite enhanced phagocytosis, infiltrating

PMN undergo apoptosis at a slower rate resulting in: 1) activated PMN secretion
of proinflammatory mediators that play a central role in pathogenesis, and 2) an
exacerbated adaptive immune response due to improper clearance by
macrophages. Consequently, clearance of apoptotic PMN is important for both
innate and adaptive immunity.

Another hallmark of chronic inflammation is the imbalance between ROS and
antioxidants in the colonic mucosa. As a result, PMN consistently produce high
levels of ROS that cause DNA damage, lipid peroxidation, and protein oxidation.
Like ROS, high levels of antimicrobial and cytotoxic proteins released by

8

degranulating PMN during post-acute colitis can contribute to DNA, lipid, and
protein damage. The presence of ROS in the colon also mediates autocrine and
paracrine signaling thereby promoting: PMN, macrophage, dendritic cell (DC),
and T lymphocyte migration into the inflamed area

45-47,74

. Several studies

suggest that PMN granule proteins, such as MPO, lipocalin-2 (LCN-2), defensin,
NE, etc., contribute to the aberrant inflammatory response associated with
colitis disease progression. Many of these molecules are present in NETs, where
they perform the same functions on trapped pathogens. Under colitis conditions,
high numbers of NETs are associated with intestinal bleeding and disease
severity. Specifically, the increased presence of NETs in the intestine has been
shown to facilitate the development of small vessel vasculitis and thrombosis
17,52,53,75 .

Clearly, PMN infiltration and response is a major contributor to colitis
pathology. Loss or inhibition of these functions can also promote chronic
inflammation. Research shows that impairment of PMN migration by blockade
of CXCR2 leads to increased levels of commensal bacteria in the intestines of
dextran sodium sulfate (DSS) -induced colitis mice, a common model of
ulcerative colitis

25,26 .

The intricate role of PMN in the transition between acute

and chronic/post-acute colitis makes it difficult to target these leukocytes and
their functions. Therefore, there is a need for the development of novel methods
that can be used to regulate PMN recruitment and responses under chronic
inflammatory conditions.

9

1.2.2.2 Reprogramming of the bone marrow myeloid compartment under
chronic inflammatory conditions
Our group previously published a study investigating the dynamic regulation of
PMN in both acute and chronic models of inflammation 1 . It was found that
PMN were altered in the BM of colitis mice and that this directly contributed to
enhanced infiltration of PMN into the colon. In these experiments, an acute
inflammatory model, specifically zymosan-induced peritonitis was used as an in
vivo PMN migration assay. Briefly, zymosan peritonitis was induced in mice
previously treated with low doses of DSS in water for 14 days (14d) to examine
PMN response. It was found that ~80% of PMN from chronically inflamed mice
appear in the peritoneal cavity within 2 hours, compared to healthy mice in
which ~80% of PMN enter between 4-6 hours. Furthermore, adoptive transfer of
BM leukocytes from healthy and chronically inflamed mice to healthy mice
revealed that PMN are functionally altered in the BM of mice during chronic
inflammation and that this contributed to enhanced infiltration and
inflammation.

While this paper provided critical insight into the effects of chronic
inflammation on PMN infiltration and response, it left open the question of their
reprogramming in the BM these mice. The purpose of my dissertation was to
investigate the reprogramming of the BM myeloid compartment under chronic
inflammatory conditions. Using a DSS-induced colitis-to-recovery model, my
research focused on answering the following unresolved questions: 1) does
reprogramming of the myeloid compartment truly occur in the BM , 2) If so,
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what is the functional significance of this reprogramming, and 3) what factor(s)
are associated with alterations to the myeloid compartment? Indeed, my
research shows that PMN become functionally primed in the BM of colitis mice,
where they display enhanced pathogen killing and migratory capabilities.
Importantly, we found that the immature myeloid population expand to become
immunosuppressive granulocytes with high expression of CXCR2. Along with
enhanced ROS production and migratory potential, these granulocytes also
displayed characteristics of myeloid derived suppressor cells (MDSC). While the
role of these leukocytes is unclear, the data suggest they may be involved in
inflammation resolution and tissue repair.
1.2.3 Myeloid-derived suppressor cells arise during ulcerative colitis
MDSC are immunosuppressive myeloid leukocytes that arise under pathological
conditions including chronic inflammation

76-78 .

MDSC are derived from

common myeloid progenitor cells and are regulated by growth factors,
granulocyte monocyte-colony stimulating factor (GM-CSF), granulocyte- colony
stimulating factor (G-CSF), and monocyte- colony stimulating factor (M-CSF),
which are also responsible for myelopoiesis at homeostasis

79-81 .

Persistent

proinflammatory signals from the inflamed area induce emergency myelopoiesis
in the BM to satisfy the increased need for myeloid cells

82-88 .

During acute

inflammation, elevated levels of CSFs in the serum encourage the egress of
immature myeloid leukocytes from the BM before maturation to replenish the
circulating PMN population. When the inflammatory condition becomes chronic,
it is hypothesized that a portion of these leukocytes expand in the BM and
differentiate into MDSC in circulation after encountering certain signals

89-92 .
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However, new evidence has emerged that suggest otherwise. Specifically, we
provide evidence demonstrating that immature myeloid leukocytes isolated from
the BM of DSS colitis mice at the post-acute/chronic phase of treatment already
display phenotypic, migratory, and immunosuppressive characteristics of MDSC.
Additionally, extramedullary myelopoiesis was observed in the spleens of these
mice. Expansion of MDSC in both the BM and peripheral organs of colitis
patients is commonly observed. Despite this, few studies have investigated BM
functional reprogramming of immature myeloid leukocytes into MDSC during
colitis

85,93-96 .

MDSC are not a defined subset of myeloid leukocytes but are instead a
heterogeneous population of granulocyte and monocyte-like cells arrested at
various stages of maturation

97-100 .

These cells are classified as immature due to

their lack of common activation and maturation markers. Additionally, they
express a mixture of surface markers specific to myeloid leukocytes but do not
express lineage markers for T lymphocytes, macrophages, and dendritic cells.
Murine MDSC are broadly defined by their expression of cell surface markers
CD11b and Gr1. The Gr1 marker has two isoforms, Lymphocyte antigen 6
complex C and G; Ly6C is traditionally expressed on monocytes while Ly6G is
expressed on the surface of granulocytes (PMN). Researchers use the differential
expression of these isoforms to characterize murine MDSC into two main
groups, as either M-MDSC or G-MDSC. M-MDSC morphologically resemble
mononuclear cells, while G-MDSC have been found to be multinucleated and
have granules like PMN. Recently, multiple new subtypes of immunosuppressive

12

myeloid leukocytes have been identified in humans. Many surface phenotypes
have been observed, with significant differences found between individuals with
the same pathological conditions

101-105 .

This indicates the presence of distinct

MDSC populations outside of the traditional M-MDSC and G-MDSC subsets
found in mice. While MDSC phenotypes have been thoroughly characterized in
mice with colitis, the role they play in its pathology remains unclear.
1.2.3.1 Characteristics of MDSC
MDSCs undergoing expansion and reprogramming acquire at least two new
capabilities. The first is the ability to exit the BM before maturation and
activation. Under healthy and acute inflammatory conditions, the immature
myeloid population is sequestered in the BM where they help to maintain an
immunosuppressive environment. Other studies have also detected small
numbers of MDSC in the spleen and peripheral blood of mice that display basal
level suppressive activity, which is likely used to control immune cell tolerance
in these areas

103,106-108 .

It is reported that MDSC exit the BM during emergency

myelopoiesis when inflammatory immature myeloid leukocytes are released to
assist circulating PMN. Circulating MDSC potently suppress CD4 and CD8
effector T cell responses through various mechanisms, not only at the site of
inflammation, but also in lymphoid organs (Fig. 1.1)

109,110 .
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Figure 1.1:MDSC mediated suppression of T cells:
Diagram depicts the known methods of MDSC suppression of
T cell proliferation, activation, and migration.

1.2.3.2 Induction and functions of MDSC specific arginase-1
The best studied mechanism of MDSC suppression is the depletion of Larginine (L-arg) in the microenvironment by arginase-1 (ARG-1)/ inducible
nitric oxide synthase (iNOS). L-arg is required for T cell development,
expansion, and activation. MDSC increase expression of ARG-1 to consume L-arg
from the microenvironment. Removal of L-arg from the microenvironment can
impair expression of the CD3ζ chain needed to complete the T cell receptor
(TCR) complex before it can be expressed on the surface of T cells, thereby

14

inhibiting their activation. In general, lack of L-arg in the microenvironment has
been correlated with global decreases in protein translation, especially those
proteins required for T cell cycle progression in

94,111,112 .

Despite this, there is no

evidence to support a direct contribution of ARG-1 to MDSC-mediated T cell
suppression.

The indirect/direct contribution of ARG-1 to MDSC T cell suppressive functions
is still up for debate. Many articles indicate a direct role for ARG-1 in T cell
inhibition but have not been able to identify an exact mechanism

110,113-115 .

Conversely, there is strong evidence to support that ARG-1 is not required for
MDSC-mediated inhibition of T cell proliferation. In one of our studies, MDSCs
isolated from the BM of tumor-bearing mice were co-cultured with splenic T
cells, in which T cell proliferation was subsequently induced by TCR-ligation,
Concanavalin A, PMA plus ionomycin, or IL-2

116 .

Although they were found to

potently inhibit T cell proliferation, independent of the method of activation,
only MDSC cultured with TCR-activated T cells or their media collected after
proliferation induced ARG-1 expression. To be specific, ARG-1 expression can be
induced in MDSC by T cell secreted cytokines IL-6, GM-CSF, IL-4, and IL-10.
Despite displaying immunosuppressive capacity, the lack of ARG-1 expression
implies that it is not constitutively expressed in MDSC and as such their
suppressive effects can be independent of its activity. Furthermore, transwell
assays helped determine that MDSC-mediated T cell suppression is likely
dependent on cell to cell contact not regulated by programmed death-ligand 1
(PD-L1) or signal regulatory proteinα (SIRPα). Despite the discrepancies
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regarding the contribution of ARG-1 to MDSC-mediated suppression, its
expression can be used as a marker to identify MDSC, as only they and M2
macrophages express ARG-1.
1.2.3.3 Inhibition of T cell responses by ROS and iNOS
G- and M- MDSC both possess ARG-1 but are thought to differentially express
ROS and iNOS, which acts independently of or cooperatively with ARG-1 to
supplement its suppressive activity

83,117 .

Murine G-MDSC predominantly use

NADPH oxidase to produce ROS that inhibit T cells. Release of ROS, especially
hydrogen peroxide (H 2 O 2 ), by G-MDSC acts to impair immature myeloid cell
differentiation into macrophages and DCs

118,119 .

On the other hand, murine M-

MDSC use iNOS to metabolize L-arg, resulting in production of nitric oxide
(NO). M-MDSC secreted NO exerts its immunosuppressive effects on T cells by
inhibiting Janus kinase (JAK) and signal transducer and activator of
transcription 3 (STAT3) signaling, reducing major histocompatibility complex
(MHC) class II surface expression, and inducing T cell apoptosis

120-123 .

In humans, all MDSC phenotypes produce ROS. As a result, ROS often combine
with NO to generate peroxynitrite, the strongest oxidant in the body

83,119,124 .

Peroxynitrite is produced upon direct contact with T cells and its production has
been shown to prevent tyrosine phosphorylation of proteins required for T cell
activation

125 .

Production of peroxynitrite results in nitration of TCR and CD8

receptor proteins, this causes structural changes in the TCR-CD3 complex that
reduce the required physical interaction between CD8 and the TCR. Thus,

16

peroxynitrite expression by MDSC leads to loss of TCR antigen recognition and
disruption of downstream signaling

108,118,126 .

1.2.3.4 Contribution of surface proteins to MDSC mediated T cell suppression
MDSC constitutively express ADAM17, a membrane-bound enzyme, that cleaves
L-selectin on the surface of T cells in circulation. Cleavage of L-selectin hinders
migration of naïve T cells into the lymph nodes and inflamed area limiting their
ability to be activated

87,88,97,127 .

Outside of ADAM17, high surface expression of

PD-L1 can directly initiate T cell exhaustion/apoptosis. Ligation of the PD-1
receptor on the surface of T cells promotes phosphorylation of SHP-2 which
inhibits downstream signaling events required for T cell growth, activation,
survival, and effector functions

87,88,97 .

It should be noted that MDSC were found

to exhibit suppressive effects on leukocytes other than T cells including PMN,
Macrophages, and NK cells. MDSC have also been shown to induce polarization
of immunosuppressive leukocytes such as regulatory T cells, M2 macrophages,
and proinflammatory T helper17 (TH17) cells

88,99,103,128-130 .

1.2.3.5 Potential roles for MDSC in ulcerative colitis
Multiple papers have reported the presence of MDSC in the blood and spleens of
chronically inflamed humans and mice

76,96 .

MDSC were found to alleviate

symptoms in animal models of rheumatoid arthritis and experimental
autoimmune encephalomyelitis (EAE)

131-136 .

MDSC have also been observed in

the blood, spleens, and colons of ulcerative colitis patients and mice models
95,137 .

Initially, MDSC were thought to play an immunosuppressive role in colitis,
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but since then their role has become controversial as recent studies have
suggested that it can contribute to proinflammatory responses.
On one hand, adoptive transfer of MDSC to colitis mice reduced inflammation
and facilitated colonic mucosal healing. This was also observed in TNBS-induced
colitis mice, where adoptive transfer of colitis expanded MDSC significantly
suppressed inflammation and down-regulated cytokine production of IL-17,
TNF-α, and IFN-γ in the colonic mucosa

138,139 .

G-MDSC expanded from healthy

immature myeloid leukocytes and transferred into colitis mice increased their
survival rate and decreased injury scores, myeloperoxidase activities, and IL-6
levels

140 .

Taken together, these findings suggest a protective role for MDSC in

intestinal inflammation.

On the other hand, there is evidence that these cells can switch to an
inflammatory phenotype under colitis conditions. Specifically, G-MDSC- like
cells in the colon of mice with colitis gained antigen presenting cells (APC)
functions, induced T cell activation, and pro-inflammatory cytokine production
54,96 .

Furthermore, MDSC mediated polarization of CD4 T cells into Th17 and

subsequent production of IL-17 has been recorded in chronic colitis patients and
mice models. High numbers of TH17 cells in the intestine and elevated IL-17
expression in the serum has been associated with colitis severity and progression
54,141,142 .

The controversial role of MDSC could partially be contributed to the

production of IL-17, as articles have demonstrated both a pathogenic and
protective role of IL-17 in intestinal inflammation

143,144 .

Understanding the role
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of MDSC during post-acute/chronic colitis is important for determining their
therapeutic potential.
1.2.4 The controversial role of IL-17 in ulcerative colitis
1.2.4.1 Production of IL-17 by Th17 cells
IL-17 is a proinflammatory cytokine that is predominantly secreted by TH17
145,146 .

TH17 cells are a distinct subset of CD4+ effector cells initially

characterized by their expression of IL-17F. Since then, TH17 cells have also
been found to secrete IL-21, IL-22, GM-CSF, IL-8, and IL-10. In healthy
individuals, differentiation of CD4+ T cells into the TH17 phenotype is
dependent upon stimulation with IL-1β, IL-6, IL-23, and TGF-β

147-149 .

However,

under chronic colitis conditions, several factors have been found to induce their
polarization.

These cells are important for maintaining mucosal immunity homeostasis.
Under healthy conditions, most of the body’s TH17 cells are found in the
intestinal lamina propria. Here, they secrete IL-17 to induce production of
intestinal antimicrobial proteins crucial for regulating commensal bacteria
tolerance

150,151 .

Additionally, IL-17 secreted in the intestinal lamina propria

facilitates epithelial cell repair and is important for maintenance of tight
epithelial cell junctions

152,153 .

The signaling events initiated by IL-17 ligation of

its receptor are required for host immune defense.
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1.2.4.2 IL-17 receptor activation and signaling
The IL-17 receptor is widely expressed on cells throughout the body, but the
strongest responses occur in PMN, fibroblast, epithelial cells, endothelial cells,
macrophages, and dendritic cells

154-156 .

Signal transduction through the IL-17A

receptor (IL-17R) requires 1) homodimers of IL-17A or heterodimers of IL-17A
and IL-17F binding to the receptor and 2) recruitment of the IL-17RC subunit to
the IL-17RA subunit after ligand binding

157,158 .

IL-17 induced signal

transduction induces activation of multiple pro-inflammatory pathways.
However, due to IL-17RAs lack of homology to other well-described receptors, its
mechanism of signal transduction is still under investigation.

IL-17 signaling is shown to activate the nuclear factor- κB (NF-κB) pathway, and
this action is facilitated by recruitment of the ACT1 adaptor protein. Once
recruited, ACT 1 binds TRAF6 and 3, which complexes with TAK1. TAK1
phosphorylates the inhibitor of NF-κB (IκB) thereby allowing the subunits of
NF-κB to translocate to the nucleus and target genes that regulate migration,
proliferation, and cytokine/chemokine production 159,160 . Studies show that IL-17
also induces activation of multiple MAPKs. However, the key role of IL-17
activated MAPK is suggested to be regulation of mRNA transcript stability.
MAPK phosphorylates destabilizing proteins that act on IL-17 target genes.
Phosphorylation of these proteins inhibits their ability to recruit the degradative
machinery, in turn increasing the concentration of target mRNAs

161,162 .
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Transcription factor C/EBPβ is activated by IL-17, as well. Its activation is
initiated upon phosphorylation by ERK and after one hour of IL-17 stimulation,
C/EBPβ is phosphorylated again at an alternative site by glycogen synthase
kinase 3β (GSK3β). The purpose of this dual phosphorylation is to downregulate
transcriptional effects C/EBPβ. The promoters of IL-17’s target genes are
enriched for C/EBP- binding elements. Specifically, activation of proinflammatory IL-6 is dependent on its binding

162-164 .

Based on this information,

it has been suggested that the IL-17 mediated-sequential phosphorylation of
C/EBPβ plays a role in the dynamic regulation of the inflammatory response.
1.2.4.3 IL-17s contribution to ulcerative colitis pathology
IL-17 is a potent regulator of host immune responses. The overexpression of this
cytokine has also been identified as one of the major contributors to chronic
inflammatory pathology

1,63,154,165,166 .

IL-17 is significantly elevated in the

inflamed intestinal mucosa during colitis. IL-17 is the predominant cytokine in
the serum, which suggests the ability to systemically regulate inflammatory
processes. Expansion of TH17 cells in the inflamed lamina propria of the colon
has also been documented

149,167 .

Like MDSC, the role of IL-17 in colitis pathology is controversial. Some studies
argue for a pathogenic role of IL-17 in colitis, as it triggers release of soluble
factors such as CXCL1, CXCL8, and Il-6. These factors activate and recruit PMN,
T cells, and NK cells, whose accumulation in the colon has been tightly
correlated with colitis disease progression

145,168 .

Induction of colitis in IL-17

knockout mice yielded no inflammation. In another study, antibody-mediated
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neutralization of IL-17 in colitis mice led to aggravation of the disease condition
156,169,170 .

These findings indicate that IL-17 is required for inflammation

initiation but may also play a role in its resolution.
1.3 Significance
In this study, ulcerative colitis is primarily used a model to study regulation of
PMN infiltration and response during chronic inflammation. Indeed, this
research is significant because it will provide further insight into the
mechanisms governing post-acute/chronic colitis progression. Colitis pathology
is intricate and multifactorial. Ulcerative colitis is a chronic, incurable disease
that affects roughly 900,000 Americans. This disease is most prevalent in
developed countries, with the highest incidence rates reported in Denmark,
Iceland, and the United States. An estimated 38,000 people in the U.S. are
diagnosed with colitis each year. The financial burden of IBD in the U.S. is more
than 30 million dollars, while colitis alone has been shown to cost the
government about $15,000 per person annually

58,66 .

Hence, there is a dire need

to understand the mechanisms underlying colitis. Understanding these
processes will be instrumental in developing strategies needed for the control
and prevention of this disease.

Clinical therapeutic options include steroids, antibiotics, and biologicals.
Steroidal medicines such as prednisone, are used to decrease inflammation
either at the intestinal wall or by inhibiting the body’s ability to mount and
maintain the inflammatory response. Medicines such as these are useful for
treating temporary flare-ups, but because of their capacity to limit the
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inflammatory response, long-term use of steroids can lead to subsequent
infections

56,171-173 .

Antibiotics slightly benefit patients with Crohn’s disease.

However, there is no significant scientific evidence to support antibiotic
treatment of ulcerative colitis

56,58,172,173 .

Recently, biologicals have become a

popular course of therapy for colitis patients. Infliximab and its counterparts
target the pro-inflammatory tumor necrosis factor (TNF) pathway by binding
with high avidity to both soluble and transmembrane forms of the protein. This
binding prevents TNF interaction with TNF receptors on the surface of proinflammatory immune cells, which decreases cytokine secretion and induces
apoptosis of these cells. Unfortunately, there is a high rate of reduced
responsiveness to these drugs

58,172,173 .

The lack of satisfactory therapeutic options creates an urgent need for effective
curative medical treatments. The research conducted expanded our knowledge of
both PMN and MDSC regulation in the BM of chronically inflamed mice.
Furthermore, it suggested a potential anti-inflammatory role for BM MDSC in
post-acute colitis. Understanding the underlying mechanisms behind their
reprogramming and expansion will enhance the potential of MDSC to be used as
a treatment or target, which can provide an effective alternative to current
options.
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1.4 Murine Disease Models
1.4.1 DSS colitis-to-recovery
A variety of animal models have been developed to investigate the pathogenesis
of human ulcerative colitis. No single model can completely recapitulate the
functional, histopathological, and immunological components of human disease.
However, the collective data obtained from these animal models have helped to
elucidate the mechanisms of ulcerative colitis disease progression

174,175 .

The

most commonly used murine model of colitis employs dextran sodium sulfate
(DSS), a heparin-like polysaccharide, that acts as a colitogenic agent to induce
epithelial damage. Due to the rapid rate of induction, reproducibility, and
simplicity of this model it is widely used in colitis research

176,177 .

In relation to

our research specifically, DSS-induced colitis has been shown to induce PMN
infiltration into the lamina propria and submucosa and trigger the inflammatory
response. Progression of treatment to the chronic stage is marked by transepithelial migration of PMN, which causes the cryptitis and crypt abscesses
frequently found in human disease

178 .

Infiltration of myeloid leukocytes perpetuates the epithelial damage initiated by
the chemical DSS. Many of the inflammatory mediators regulating PMN
infiltration and response become elevated in the tissues and serum of this
treatment model. In the acute colitis model, (1-2%, given 5-7 d) expression of
TNFα, IL-6, IL-1β, and IL-8 in tissues is significantly increased. Chronic DSSinduced colitis (2-5%, given 9-14 d or in repeated cycles) leads to polarization of
TH2 cells, culminating in decreased expression of proinflammatory cytokine
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TNF-α and increased levels of IL-10, Il-4, IL-6, and IFN-γ

179-182 .

Furthermore,

high expression of IL-17 has been reported in the tissue and serum of DSSinduced colitis mice at the post-acute/chronic stage of treatment, which
resembles human ulcerative colitis

1,140,179 .

According to our studies and studies

by others, IL-17 can induce an exaggerated PMN response during DSS colitis
through at least two mechanisms, 1) promoting granulopoiesis, thereby
replenishing the PMN supply, and 2) potentiating PMN response causing
enhanced PMN chemotaxis, ROS production, etc.

148,156,168 .

Mice can be made to morphologically and symptomatically model acute and
chronic colitis, respectively, by modifying the concentration, duration, and
frequency of treatment with DSS. The molecular weight of DSS is crucial for
colitis induction and progression. Most protocols use 40-50 kDa of DSS to
achieve both an acute and chronic inflammatory state in the colon, where
disease severity can be controlled by changing the conditions mentioned above
178,181-183 .

In addition to molecular weight, mice strain, sex, and gut microbial

environment all contribute to disease development

184,185 .

To induce colitis, DSS

is administered to mice in tissue culture grade water. While the exact method of
DSS induction is still being debated, the common theory is that it disrupts the
intestinal epithelial monolayer lining, which in turn activates the inflammatory
response. The sulfated polysaccharide does not directly induce intestinal
inflammation, but instead acts as a chemical toxin to damage colonic epithelium
causing epithelial cell injury

186-188 .
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1.4.1.1 DSS disrupts mucosal barrier function
Administration of DSS, leads to weakening of the distal colon epithelial lining
resulting in entry of luminal commensal bacteria and associated antigens into
the mucosa. This allows potentially pathogenic intestinal components (e.g.,
bacteria and their products) into the lamina propria 174,186 . The mechanism of
how DSS disrupts the distal colon is still under investigation. Many studies
report that, like ulcerative colitis patients, mice treated with DSS exhibit altered
tight junction complexes coupled with subsequent increases in colonic
permeability. Therefore, the increase in colonic mucosal permeability is
considered the first event, followed by breaches in the mucosa barrier that allow
the influx of inflammatory cells into the intestinal mucosa

189,190 .

Additionally,

some studies suggest that dextran sulfate inhibits ribonuclease action, but the
mechanism of how DSS penetrates the cell is also unclear

191,192 .

Recent studies

indicate that DSS combines with medium-chain-length fatty acids that are
present in the colonic lumen to form nano-lipocomplexes, which can fuse with
colonocyte membranes and further activate downstream inflammatory signaling
pathways inside the cytoplasm

193 .

1.4.1.2 Mucin in DSS-induced colitis pathology
Intestinal mucus is crucial for efficient barrier function, as it contains
proteins required for epithelial barrier integrity. The colon mucosa is comprised
of both secreted and membrane bound forms of glycoproteins named mucins
194,195 .

Secreted gel-forming mucins protect the epithelium from commensal

microbiota in the colon by covering it to provide a mucosal barrier. As
membrane bound forms of mucin possess transmembrane regions, they have
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been implicated in cell signaling, adhesion, and growth. Additionally, membrane
bound mucin have been found to modulate the immune response by activating
downstream signaling pathways that activate leukocytes

196,197 .

These proteins become altered in patients with colonic inflammation and
contribute to dysregulation of barrier functions. In MUC2 (the primary mucin
present in the colon) knockout mice, decreases in mucus gel thickness occurred
at the same time mice begin to display symptoms of DSS treatment. Studies
show that post-translational modifications are important for MUC2 function as
well. During acute DSS-induced colitis, decreased sulfation of MUC2 results in a
failure to control inflammation, even though its expression is temporarily
increased. Changes to the glycosylation of these proteins impair MUC2
synthesis, which weakens barrier integrity to increase susceptibility to DSS
treatment

198 .

Conversely, deletion of transmembrane MUC 1 and 4 proteins

resulted in protection of the intestinal epithelium and resistance to DSS-induced
colitis

194,196,197 .

Altogether the findings discussed here suggest that DSS

treatment also modifies the mucosal barrier structure to promote disease
development.
1.4.1.3 DSS effect on commensal bacteria
Research investigating the role of gut commensal microbiota in the pathogenesis
of intestinal inflammation has become popular in recent years. Many studies
demonstrate changes to the microbiota of DSS mice, as early as the acute phase,
at 3 days (3d), like those in colitis patients

199,200 .

Specifically, the anti-

inflammatory populations of bacteria that regulate homeostasis in healthy
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colons, such as Bacteroidetes, Prevotella, Clostridium, and Lactobacillus were
reduced in mice treated with DSS. This decrease was coupled with expansion of
pro-inflammatory microbial genera in the colon. Compositional changes to the
microbiome further promote pathogenesis of colitis, especially in the case of
Faecalibacterium prausnitzii. Diminishment of F. prausnitzii, enhances
synthesis of proinflammatory cytokines in the colon through activation of the
NF-κB pathway and induction of IL-8

180,201,202 .

Clearly, murine DSS treatment

mimics the effect of human ulcerative colitis on the microbiota. Interestingly, in
studies where DSS was removed, populations of healthy colonic commensal
bacteria were rapidly restored

180,189 .

Post-treatment, anti-inflammatory

intestinal microbiota became abundant, even when compared to healthy
animals. Nevertheless, the various methods used by DSS to induce colitis
collectively promote development of colonic inflammation, that resembles
ulcerative colitis in humans. These underlying mechanisms are
directly/indirectly associated with manifestation of colitis symptoms including
significant weight loss, diarrhea, bloody stool, reduced colon length, loss of
colon epithelial tissue, and crypt architecture disruption

66 .

We created a 2% DSS-induced colitis-to-recovery mice model to investigate
leukocyte response under acute, post-acute/chronic, and resolution conditions
(Fig. 1.2). To do this, mice received 2% DSS dissolved in tissue culture grade
water

1,203 .

Mice were treated for 9 days (9d) consecutively to induce chronic

colitis and then allowed to recover for ~21 days (21d). The symptoms mentioned
above were monitored to follow disease progression. Indeed, we show that
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colitis-to-recovery mice exhibit body weight loss, colon tissue loss, and bloody
diarrhea associated with the inflammatory response elicited by DSS.
Furthermore, high expression of IL-17 in the serum of our mice resembled what
is seen in the human condition. Ultimately, DSS induction of colitis is a simple
and controllable animal model to study PMN infiltration and response, due to its
similarity to human ulcerative colitis.

Figure 1.2: Scheme of DSS-induced colitis–recovery model in C57BL/6 mice.
Mice (~20g) were treated with 2% DSS in drinking water for 9 d, followed by 21
d of pure water. Indicators of disease progression and recovery were then
monitored.

1.4.2 Zymosan-induced peritonitis as a PMN response assay
Zymosan-induced peritonitis is a robust model of self-resolving acute
inflammation. Intraperitoneal injection of zymosan increases vascular
permeability and transiently activates the inflammatory reaction. The response
elicited by treatment mimics characteristics of acute inflammation including
pain, synthesis of pro-inflammatory mediators, and leukocyte infiltration

204-207 .

While zymosan has been shown to activate macrophages and natural killer (NK)
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cells, its ability to recruit PMN in to the peritoneum within 4-6 hours makes it
an excellent method to assay their response 1 . Despite this, development of
peritonitis is dependent upon secretion of proinflammatory mediators by
activated peritoneal macrophages. PMN and macrophages also play a
collaborative role during the end of inflammation, as PMN apoptosis and
subsequent efficient clearance by macrophages is required for resolution of this
model

10,208-210 .

Zymosan is a component of the yeast cell wall that is primarily composed of βglucans or polymers of D-glucose. These β-glucans along with other components
of zymosan including mannans, chitin, and lipids have been shown to activate
various pattern recognition receptors (PRR) on the surface of peritoneal
macrophages

207,211 .

Specifically, β-glucan ligation of dectin-1 receptor and TLR2

leads to production of histamine and leukotrienes that increase vascular
permeability, thereby promoting leukocyte infiltration

204,205,208,211,212 .

Ligation

of TLR2 on peritoneal macrophages has also been shown to activate
transcription factor NF-κB and induce secretion of pro-inflammatory
cytokines/chemokines TNF-α, IL-8, and ββ

208,212,213 .

As a result, macrophages

are thought to orchestrate inflammation onset in this animal model through
selective secretion of inflammatory mediators.

For my research, adoptive transfer experiments were coupled with zymosaninduced peritonitis to assay the response of BM myeloid leukocytes under
chronic inflammatory conditions. Myeloid leukocytes isolated from the BM of
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mice treated with 2% DSS were fluorescently labeled and intravenously injected
into healthy donor mice. Following this, 0.25mg of zymosan was injected into
the peritoneal cavity to induce infiltration of the transferred cells. It was found
that ~80% of myeloid leukocytes from chronically inflamed mice infiltrated the
peritoneum by 2.5 hrs compared to healthy myeloid leukocytes, which arrive
within 4-6 hrs. These data suggest that BM myeloid populations demonstrate
enhanced responses during chronic inflammation. Taken together, these studies
confirm the value of zymosan-induced peritonitis as both a self-resolving model
of acute inflammation and PMN response assay.
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2

CYTOKINE REGULATION OF MYELOID LEUKOCYTES UNDER
INFLAMMATORY CONDITIONS

2.1 Chapter Introduction
Cytokines and soluble mediators are important for homeostasis and proper
balance of immune function. However, increased or continuous expression of
these factors has been implicated in the pathogenesis of both clinical and
experimental models of ulcerative colitis

2,64,179 .

During intestinal inflammation,

a wide variety of cytokines, chemokines, and other pro-inflammatory factors are
produced by T cells, macrophages, and neutrophils. Studies show that increased
polarization of Th1 cells during intestinal inflammation leads to elevated levels
of pro-inflammatory cytokines such as TNF-α and IFN-γ, which have been
identified as major contributors to ulcerative colitis progression. Proinflammatory mediators released during chronic inflammation also control
leukocyte activation, recruitment, and effector functions

64,214 .

Therefore, the

abundance of factors such as TNF-α, IL-6, IFN-γ, GM-CSF, IL-8, and IL-17 in
the inflamed colon and serum of colitis patients promotes the continuous
infiltration of inflammatory cells and their enhanced response, all of which
contribute to disease pathology. Although several articles have investigated
cytokine regulation of leukocyte responses during chronic colitis, the effect of
pro-inflammatory mediators on the myeloid population is still unclear. This
chapter focuses on reviewing the literature on mechanisms underlying cytokine
regulation of myeloid leukocyte recruitment, infiltration, and response during
ulcerative colitis.
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2.2 Pro-inflammatory Regulators of PMN Response During Colitis
Pro-inflammatory cytokines regulate PMN recruitment and response by binding
their respective receptors on the cell surface and initiating signal transduction,
which has been shown to predominantly activate transcription factors
MAPK/extracellular signal-regulated kinase (MEK-ERK), MAPK kinase 3/6
(MKK3/6-p38 MAPK), phosphatidylinositol 3-kinase (PI3K), and NF-κB. The
primary pro-inflammatory cytokines shown to rapidly activate these pathways
are G-CSF, GM-CSF, TNF-α, and interleukin-1β

18,215,216 .

It should be noted that

IL-6 and IL-17 have also been identified as major regulators of PMN responses,
but this will be further discussed in a separate section. While these factors have
been shown to regulate multiple cellular processes including ROS production,
adhesion, cytoskeletal remodeling, migration, and apoptosis, the effect of each
depends on the activating cytokines

217 .

Pro-inflammatory cytokines act

collaboratively to support the host immune response, but under ulcerative colitis
conditions the excessive stimulation of PMN significantly contributes to disease
progression.
2.2.1 Cytokine regulation of PMN migration
Multiple pro-inflammatory factors have been found to mediate PMN recruitment
and migration during inflammation. G-CSF, GM-CSF, and TNF-α especially have
been shown to regulate PMN adhesion and chemotaxis. In ulcerative colitis
patients and animal models, G-CSF promoted enhanced PMN motility that
contributed not only to PMN infiltration of the colon but also to their rapid
mobilization from the bone marrow (BM). Additionally, GM-CSF and TNF-α
were found to induce β2 integrin–dependent adherence, suggesting a role in
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transmigration

18,218,219 .

When PMN arrive in the inflamed area, they use

chemotaxis to locate and uptake the insult. To do this, they rapidly polymerize
and depolymerize actin filaments to create the leading edge or lamellipodia,
which is required for crawling. In vivo experiments revealed that stimulation of
PMN with G-CSF results in protrusion of lamellipodia. Furthermore, activation
of human PMN with G-CSF, GM-CSF, or TNF-α induced actin depolymerization
thereby mediating cytoskeletal remodeling

18,217-219 .

2.2.2 Control of PMN effector functions by inflammatory mediators
Release of ROS is a major effector function of PMN that is crucial for removal of
pathogen. In ulcerative colitis, enhanced ROS production by PMN contributes to
tissue damage in the intestines. Activation of the MEK-ERK and MKK3/6-p38
MAPK pathways by GM-CSF, TNF-α, and IL-1β have been implicated in the
production of ROS via activation of NADPH oxidase

18,215 .

These findings

indicate that GM-CSF, TNF-α, and IL-1β contribute to ROS induced tissue
damage during intestinal inflammation. Enhanced ROS production coincides
with decreased apoptosis in PMN of humans and mice with chronic colitis. Prolonged PMN life span in the colon is a driving factor of ulcerative colitis
pathology. Delayed PMN apoptosis may be due to cytokine regulation of
intracellular apoptotic molecules. IFN-γ and TNF-α activation of NF-κB was
found to have an anti-apoptotic effect in human PMN. G-CSF was also found to
induce expression of inhibitor of apoptosis protein cIAP2, which prevents
translocation of pro-apoptotic Bcl-2 family proteins

70,71,220 .

The studies

discussed clearly indicate the importance of pro-inflammatory cytokines in the
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regulation of PMN infiltration and responses and how their presence contributes
to intestinal inflammation.
2.3 IL-17 Regulation of the Bone Marrow Myeloid Compartment in
Ulcerative Colitis
IL-17 is significantly elevated in the serum and inflamed mucosa of ulcerative
colitis patients and mice models. As shown in figure 2.1, the primary cytokine
present in the serum of DSS colitis mice is IL-17, suggesting its ability to
systematically regulate the inflammatory response

149,156 .

In particular, IL-17’s

regulation of PMN differentiation, activation, and recruitment from the BM
indicates that it is a crucial regulator of inflammatory responses

155,159,161-164,166 .

IL-17’s ability to induce production of other pro-inflammatory factors such as
IL-6, GM-CSF, TNF-α, IL-1β, IL-8,CXCL1 and G-CSF in leukocytes, especially
PMN has been identified as a major contributor to ulcerative colitis pathology
1,149,154 .

IL-17 has also been shown to regulate PMN effector functions through

induction of nitric oxide, MMPs, β-defensin, and etc.

1,143,146,156,217,221

. Under

chronic colitis conditions, IL-17 induced retinoic-acid-related orphan receptor
C1 (RORC1) expression was found to drive emergency myelopoiesis via
activation of transcription factors NF-κB, P38/MAPK, C/EBPβ (CCAATenhancer-binding protein-β) and SOCS3 (suppressor of cytokine signaling 3)
223 .

221-

These findings indicate the deleterious effect of IL-17 in ulcerative colitis

pathology. However, induction of colitis in IL-17 knockout mice yielded no
intestinal inflammation, while antibody-mediated neutralization of IL-17 in
colitis mice led to the aggravation of the disease

143,144,169,221,224 .

Therefore, these
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findings suggest that IL-17 promotes colitis disease progression, it may also
demonstrate suppressive effects.

Figure 2.1: Expression of IL-17A during DSS-induced colitis in mice.
According to this figure, IL-17A is highly expressed at the post-acute stage of
DSS-induced colitis in mice. (Bian et al., 2012)

2.3.1 The dynamic relationship between IL-17 and MDSC during
inflammation resolution.
Several studies have examined the direct and indirect contributions of IL-17 to
the resolution of intestinal inflammation. In a clinical setting, ulcerative colitis
patients treated with antibodies against IL-17 exacerbated disease symptoms,
which implies a more complex role for IL-17 in colitis than originally thought
143,144,169 .

In this study, IL-17 was still elevated in the serum of DSS-induced
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colitis-to-recovery mice, albeit at lower levels, during inflammation resolution
when expansion of G-MDSC was observed. MDSC are a population of immature
myeloid cells arrested at various stages of differentiation and as such can be
induced by the same factors as mature PMN. IL-6 and GM-CSF, specifically,
have been shown to contribute to their induction in cancer and chronic
inflammation. Recently, other mediators have been found to induce generations
of MDSC in various models of chronic inflammation

81,102,103,116,135 .

Despite this,

all studies suggest induction of MDSC requires at least two cytokines.

IL-17 regulates production and secretion of both IL-6 and GM-CSF under
chronic inflammatory conditions. Furthermore, it has been shown to induce
secretion of other MDSC stimulatory factors such as G-CSF, IL-4, and IL-10
95,116,138,142,225 .

Our research demonstrates that immature myeloid leukocytes

collected from the BM of mice at the post-acute phase of colitis treatment
display characteristics of G-MDSC. As IL-17 is the primary cytokine systemically
present in our model at the time of MDSC expansion, it is likely that it may play
a direct/indirect role in regulating MDSC under colitis conditions. IL-17’s role in
the development of MDSC has yet to be studied in chronic inflammation.
However, recent studies indicate that IL-17 not only promotes expansion of
MDSC, but also inhibits their apoptosis in animal models of colorectal cancer
and Lewis lung carcinoma

226,227 .

On the other hand, MDSC were found to effect

TH17 cells as they inhibited TH1 responses while enhancing TH17 generation
and inducing IL-17 production in a murine model of chronic colitis

54,141 .

Taken
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together, these findings suggest that there is a dynamic relationship between IL17 and MDSC in chronic intestinal inflammation.
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3.1 Chapter Introduction
Myeloid leukocyte recruitment and responses are essential for the innate
immune response. When tissue injury, infection, or trauma occurs various cells
in the affected area including damaged epithelial cells and tissue-resident
macrophages secrete a variety of pro-inflammatory cytokines and chemokines
such as IFN-γ, IL-8, CXCL1, TNF-α, IL-6, GM-CSF and IL-17

3,32,61,204 .

These

mediators were found to orchestrate the inflammatory response primarily
through activation, recruitment, and regulation of immune cells effector
functions, especially in polymorphonuclear leukocytes (PMN). The proinflammatory mediators also alter the vasculature and microenvironment at the
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site of insult to promote PMN infiltration. PMN are the first leukocytes to arrive
at the site of inflammation and their responses are required to establish the
inflammatory response

1,5 .

PMN are mature granulocytes that express myeloid specific markers
CD11b+Ly6G hi Ly6C +. They comprise~50-60% of total circulating leukocytes in
healthy individuals. Although the life span of PMN in circulation varies in the
literature, they are considered short lived when compared to other leukocytes
such as T lymphocytes, B lymphocytes, and macrophages. To maintain their
high numbers in circulation, an average of 1.5 ×10 11 PMN are generated in the
bone marrow (BM) per day under healthy conditions

4,6

. Inflammation induces

recruitment of circulating PMN and mobilizes PMN from the BM to infiltrate the
inflamed area.

PMN become completely activated upon migration into the inflamed tissues,
resulting in secretion of anti-microbial proteins and cytotoxic enzymes including
myeloperoxidase (MPO), neutrophil elastase (NE), matrix metalloproteases
(MMPs), reactive oxygen species (ROS), and nitric oxide (NO)

15,42-48,213 .

PMN

also uptake and degrade damaged cells and pathogen using phagocytosis and
generate neutrophil extracellular traps (NETS), which are web like structures of
chromatin fibers that contain granular proteins such as NE, MPO, and ROS to
immobilize and degrade pathogen extracellularly before phagocytosis.
Additionally, PMN secretion of cytokines/ chemokines perpetuates inflammation
by recruiting macrophages, T cells, and B cells needed for the adaptive immune
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response

4,17,43,53,75 .

Studies show that apoptosis not only decreases expression of

inflammatory mediators in the tissues, but also polarizes suppressive cell types
that down regulate inflammation, thereby promoting resolution

18,20,70-72 .

In the

acute inflammatory response, clearance of pathogen and PMN apoptosis is
followed by inflammation resolution, tissue repair, and a return to homeostasis.

Failure to resolve the acute immune response results in post-acute or chronic
inflammation. A combination of genetic susceptibility, immune system
dysregulation, and microenvironmental factors are thought to initiate chronic
inflammation

4,56,59-61,178 .

As non-specific PMN responses contribute to

inflammatory pathology, they are thought to promote the development and
progression of chronic inflammation. Specifically, PMN infiltration and response
has been correlated with disease severity in several chronic inflammatory
diseases including Crohn’s disease, ulcerative colitis, and rheumatoid arthritis
11,12,43,228 .

Therefore, understanding how these leukocytes are regulated under

inflammatory conditions could provide novel therapeutic options for treatment
of the above conditions.

In our previous study, a dextran sodium sulfate (DSS)-induced colitis model was
used to investigate PMN response during chronic inflammation 1 . Briefly, mice
were given 2% DSS in water continuously to create an active inflammatory state
in the intestines. Following this zymosan-induced peritonitis, a model of acute
inflammation, was used as an in vivo response assay to examine PMN
infiltration under chronic inflammatory conditions. It was revealed PMN from

41

colitis mice infiltrated the peritoneum in less than 2.5 hours when compared to
healthy PMN that normally arrive in the peritoneum 4-6 hr after zymosan
injection. Furthermore, adoptive transfer of BM leukocytes from chronically
inflamed mice to healthy mice showed that the BM leukocytes become altered

1

This finding suggested that a reprogramming event occurs in the BM of mice
with chronic inflammation, contributing directly to enhanced infiltration during
peritonitis.

Although this study provided crucial information regarding the regulation of
PMN during chronic inflammation, some questions remain unanswered. If there
is indeed a reprogramming event that occurs in the BM myeloid compartment
under chronic inflammatory conditions, what is the functional significance of
these alterations? Additionally, we are interested in how this population changes
as inflammation is resolved. To investigate these issues, a murine DSS- induced
colitis-to-recovery model was created. Mice were treated with DSS in water for
9d, which was followed by removal of the chemical insult to allow inflammation
resolution. BM, spleens, colons, and blood were collected from treatment mice
for analysis post euthanasia at multiple time points.

Analysis of Percoll density gradient separated BM myeloid leukocytes revealed
that the mature PMN population progressively decreases during the post-acute
phase of treatment. Decreased numbers of PMN were likely a result of their
mobilization into circulation. Interestingly, the immature myeloid leukocyte
population transiently increased during the same time frame. Phenotypic and
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functional analysis of both immature and mature BM myeloid leukocytes
demonstrated that PMN isolated from the BM become functionally primed,
exhibiting enhanced ROS production and infiltration in adoptive transfer
experiments. More importantly, it was shown that chronic colitis induced
expansion of immunosuppressive granulocytes with increased expression of
myeloid migratory receptor CXCR2.

These immature granulocytes displayed enhanced ROS production and
migratory abilities like mature PMN, but also demonstrated characteristics of
myeloid derived suppressor cells as they expressed ARG-1 and gained the ability
to potently suppress T cell proliferation. Release of immature myeloid
leukocytes from the BM is common during chronic inflammation, due to
emergency myelopoiesis, a process where PMN precursors are released from the
BM to satisfy the increased need for PMN. However, these cells are generally
pro-inflammatory and do not possess suppressive functions 77,223,229 .
Furthermore, ARG-1 + immature granulocytes were identified in spleens and
colons of DSS treated mice during inflammation resolution. Taken together,
these findings suggest that reprogramming of the myeloid compartment
produces both functionally primed PMN that accelerate pathogen clearance
toward resolution and immunosuppressive granulocytes that suppress T cell
responses beginning at the post-acute/chronic phase of DSS treatment and
lasting throughout inflammation recovery.
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3.2 Materials and Methods
3.2.1 Murine DSS-induced colitis-to-recovery models:
C57BL/6 mice (6-10 weeks old, 18-22 g) were obtained from The Jackson
Laboratory (Bar Harbor, ME) and were housed in a pathogen-free facility with
access to food and water. To induce colitis, 2% dextran sodium sulfate (DSS, MP
Biomedicals) was dissolved in pure water and given to mice for drinking. Mice
were treated with DSS for 9 consecutive days, followed by up to 21 days (21d) of
non-DSS treated drinking water to allow for recovery.

Mice were examined daily to assess the level of stress, onset of colitis symptoms,
and recovery from inflammation. The disease activity index (DAI) was calculated
using an average of three criteria: 1) percentage body weight loss (0, none; 1, 15%; 2, 5-10%; 3, 10-15%; 4, >15%), 2) stool consistency (0, solid stool; 2, loose
stool; 4, diarrhea), and 3) presence of blood in stool (0, negative; 2, positive; 4,
gross bleeding) as shown in previous colitis studies

1,203 .

Serum, spleen, colon,

and BM were collected post euthanasia every three days (0, 3, 6, 9, 12, 15, 18, 21,
24, 27, 30d) for analyses.
3.2.2 Measurement of serum cytokines:
Serum was isolated from whole blood by low speed centrifugation. Cytokine
levels in the serum were assayed using the standard sandwich ELISA. Serum
samples were incubated (2 h, 25°C) in a 96-well plate coated with capture
antibodies against IL-6, IL-17, TNF-α, IFN-γ, GM-CSF, IL-10, IL-4, TGF-β, IL22. After washing, the wells were incubated with biotinylated detection
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antibodies and HRP-conjugated streptavidin, followed by color development
using OPD. Data was analyzed using SoftMax Pro microplate data software.
Purified and biotinylated antibodies against all cytokines were purchased from
BD Biosciences or BioLegend. Recombinant cytokines used as standards were
purchased from PeproTech.
3.2.3 Percoll gradients separation of bone marrow leukocytes:
Prior to preparing density gradients, Percoll (Sigma) was adjusted to 150 mM
NaCl, 325 mOsM by mixing 1-part 10× HBSS with 9-parts Percoll. Further
dilution in HBSS (v/v) produced Percoll density solutions of 70% (1.088 g/mL),
60% (1.076 g/mL), 50% (1.064 g/mL), and 40% (1.052 g/mL). Four-step
discontinuous density gradients were prepared in a 15 mL tube by successively
layering decreasing density solutions (2 mL/layer) upon one another (70, 60, 50,
and 40%) starting with the densest placed at the bottom. To better distinguish
density layers, some Percoll solutions were prepared in HBSS with phenol red to
create alternating-colored density layers. Approximately 3×10 7 - 5×10 7 BM cells
harvested from femur and tibia by flushing bone cavities followed by RBC lysis
were placed on top of the gradients in 2 mL PBS, followed by centrifugation at
1000 × g for 45 min in a swinging bucket rotor. This centrifugation resulted in
cells forming three leukocyte-enriched fractions at the density-transition
interfaces.

Cells in each band were collected, washed, and counted. FACS analysis of CD11b,
Ly6G, LY6C, and CXCR2 (antibodies from Biolegend) surface expression was
used to identify the myeloid compartment. Further separation of Ly6G+

45

granulocytic and Ly6C high monocytic leukocytes enriched in fraction III was done
using biotin-conjugated anti-Ly6G antibody and streptavidin-conjugated
magnetic microbeads, which positively selected granulocytes (>95% purity),
leaving the unbound to be majorly (>85%) of Ly6C high monocytes.
3.2.4 Immature myeloid cell and PMN functional assays:
To measure ROS production, leukocytes treated with 1 μM PMA in the presence
of 5 μM oxidation sensitive dye DCFDA (Invitrogen). After washing, DCFDA
staining was correlated with intracellular ROS production and measured by
Fluorescent Activated Cell Sorting (FACS). To test myeloid leukocyte response
during chronic inflammation-to-recovery, mature PMN or immature myeloid
cells isolated from the BM (1 × 10 7 each) were labeled with 5-(and-6) (((4chloromethyl) benzoyl) amino) tetramethyl-rhodamine [CMTMR, red] or
carboxyfluorescein diacetate succinimidyl ester (CFSE, green) respectively, and
administered (i.v.) into healthy C57BL/6 mice. Following intravenous myeloid
leukocyte administration, mice immediately received injections of PMN
activation agent zymosan (0.25 mg).

3.2.5 T cell proliferation assay:
Freshly isolated healthy splenocytes (6 ×10 5 cells/mL) labeled with
carboxyfluorescein succinimidyl ester (CFSE) were induced to proliferate in a
96-well plate that had been immobilized with anti-CD3 antibody (1 μg/mL) in
the presence of soluble anti-CD28 antibody (0.5 μg/mL, both from Biolegend) in
RPMI1640 media with 10% FBS, 2 mM L-glutamine and 50 nM β-
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mercaptoethanol for 4 days (4d) (37 ο C, 5% CO 2 ). To examine MDSC-mediated T
cell inhibition, the Fraction III (Fr. III) population of leukocytes were added into
the T-cell proliferation system at the ratio of 1:6 or 1:8 of leukocytes to
splenocytes. T-cell proliferation was then evaluated microscopically and by FACS
that determined CFSE intensity.
3.2.6 Murine tissue analysis:
To isolate cells from the spleen, spleens were emulsified in RBC lysis buffer (155
mM NH 4 Cl, 10 mM KHCO 3 , and 1 mM EDTA) at room temperature in 1× PBS
and filtered through nylon mesh with a pore size diameter of 70 μm. Cells were
collected in ice-cold 1× PBS and labeled with two combinations of fluorescenceconjugated antibodies (anti-mouse CD4 and CD8, or CD11b, Ly6C, and Ly6G) at
a concentration of 1g/mL. Cell populations were analyzed by FACS (LSR
Fortessa, BD Biosciences).

For histochemical staining, mouse colons were fixed in 4% paraformaldehyde,
embedded in Neg-50 (ThermoFisher), and cut into 5–10-mm thin sections, that
were then stained with H&E. For staining of infiltrated myeloid leukocytes and
expression of tissue repair proteins, freshly sectioned tissues were blocked with
5% BSA followed by staining using anti mouse PE-conjugated Ly6G, FITCconjugated a-SMA, PE-conjugated Ki67 Ab, and DAPI (nucleated cells). Images
were captured using a Keyence fluorescence microscope imager.
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3.2.7 Statistical analysis:
Data are presented as the mean ± SEM. Statistical differences/ significance
between data sets were assessed using the two-tailed Student's t-test for two
groups or one-way ANOVA. Dunnett’s Multiple Comparison test was used to
compare data means.
3.3 Results
3.3.1 Murine DSS-induced colitis-to-recovery model:
In this study, we investigated the reprogramming of the BM myeloid
compartment using a common model of PMN associated chronic inflammation,
DSS-induced colitis. To induce intestinal inflammation, healthy C57BL/6 mice
20g or above were given 2% DSS in water for 9d to develop an active
inflammatory state in the intestines. We modified the traditional DSS-induced
colitis model by removing the chemical insult to allow for inflammation recovery
(Fig. 3.1A). Colitis induction in mice is marked by a series of symptoms
including significant weight loss, colon shrinkage, diarrhea, and bloody stool
66,178,181,193 .

These symptoms were used as disease prognosis markers to monitor

disease development. Decrease in body weight (Fig. 3.1B), disease activity index
(DAI) (Fig. 3.1C), and colon tissue loss (Fig. 3.1D) observed at the post-acute
stage of treatment, ~9-15d, suggest that colitis was successfully established in
mice. After removal of DSS, all markers gradually returned to baseline. It should
be noted that colon morphology did not return to its original shape until after
30d (Fig. 3.1D).
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In ulcerative colitis patients, expression of IL-17 is associated with disease
pathogenesis. Several studies have reported that IL-17 is the primary cytokine
elevated in the serum of DSS-induced colitis mice as well

1,138,143,144,169,170 .

This

was recapitulated in our DSS colitis-to-recovery model, as serum IL-17
expression increased to ~2 ng/ml (3-fold) at the post-acute phase. Surprisingly,
IL-17 expression remained elevated after PMN infiltrated the intestine and did
not return to basal level until the late in inflammation resolution (~18-30d) (Fig.
3.1E). Comparably, other pro-inflammatory cytokines such as IL-6, IFN-γ, and
GM-CSF showed no significant changes in the serum.

Fecal lipocalin 2 (LCN-2), also known as neutrophil gelatinase-associated
lipocalin (NGAL) in humans, has recently been identified as a biomarker for
both active inflammation and inflammation recovery. LCN-2 is released by
degranulating PMN during active inflammation. Recently, it was shown that
LCN-2 is highly inducible in intestinal epithelial cells during tissue recovery.
Apical secretion of LCN-2 in the lumen and the ability to assay its expression in
feces suggest it acts locally during inflammation and does not get metabolized.
Due to its stable expression in the feces of mice with intestinal inflammation,
analysis of LCN-2 by ELISA has emerged as a non-invasive method to monitor
colitis disease progression

73,230-234 .

Feces collected from colitis-to-recovery mice

displayed elevated expression of LCN-2 at the post-acute phase of treatment.
Furthermore, we show that its expression continues to increase during recovery,
reaching ~5 x 10 3 ng/g of feces at 18d, thus confirming both the chronic
inflammatory and recovery aspects of our model (Fig. 3.1F).
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3.3.2 Percoll gradient separation of the BM myeloid compartment:
Percoll density gradients were employed to determine if the BM myeloid
population becomes altered in mice with chronic colitis. As shown in Fig. 3.2, a
gradient centrifugation separated BM leukocytes into four density-decreasing
fractions (Fr.) I, II, III, and IV, settled at the density
interface of 5–40, 40–50, 50–60, and 60–70%, respectively. For our purposes
Fr. I and II were combined into one Fr. that contained stromal cells, fibroblast,
and B lymphocytes (data not shown)

1,116,203,235 .

CD11b+ Gr-1+ myeloid

leukocytes were enriched in Fr. III (50-60%) and IV (60-70%). Specifically, Fr.
III was comprised of Ly6C high monocytes and low-density Ly6G + granulocytes.
Fr. IV contained mature PMN, which were LY6G + and displayed high SSC values
indicative of complex intracellular granular structures (Fig. 3.2B).

Upon identifying and isolating our target populations, each Fr. was collected,
counted, and expressed as a percentage of the total number of BM leukocytes. In
0d healthy control mice, percentages of BM cells distributed in Fr. I+II, III, and
IV were approximately 24%, 28%, and 50%, respectively. For mice at the postacute stage of colitis (9d), the percentage in Fr. III transiently increased to ~66%
and did not return to baseline until late stage recovery (18d). Concomitantly,
PMN (Fr. IV) percentage progressively decreased during active inflammation,
likely as a result of mobilization into inflamed tissues, but recovered when
inflammation subsided (Fig. 3.2C, Table 3.1).
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3.3.3 Reprograming of the BM myeloid compartment during chronic
inflammation:
Although PMN percentages significantly decrease in the BM at the post-acute
stage, enhanced ROS production was observed when leukocytes were activated
with PMA (Fig. 3.3A). To test PMN response in vivo, adoptive transfer
experiments were conducted. For these experiments, Percoll separated myeloid
leukocytes of Fr. IV collected from mice under colitis-to-recovery treatment were
labeled with CMTMR (red fluorescent dye). The labeled Fr. IV leukocytes were
transferred into healthy recipient mice, that were then intraperitoneally (IP)
injected with zymosan to induce peritonitis. Consistent with our previous
findings, analyses of the recipient mice 2.5 h later showed that leukocytes from
mice at the post-acute stage (9-15d) of treatment display significantly enhanced
infiltration into the peritoneum (Fig. 3.3B). Thus, suggesting that PMN become
functionally primed in the BM of mice with chronic colitis.

Ligation of migratory receptor CXCR2 on the surface of PMN facilitates their
release from the BM. Traditionally, immature myeloid leukocytes express low
levels of CXCR2 until maturation

12,22,24,25 .

However, it was found that chronic

inflammation induced expression of CXCR2 in the expanded population of
immature myeloid leukocytes (Fr. III) (Fig. 3.3C). Additionally, enhanced
production of ROS was observed during the post-acute phase of treatment
(Fig.3.3D). These data suggest that the immature leukocytes become effectors
cell that can be recruited into circulation by chemokines, with the ability to kill
pathogen.

51

Increased CXCR2 expression not only suggest that Fr. III leukocytes can be
recruited in to circulation, but that the changes they undergo in the BM can also
allow them to infiltrate tissues as well. To investigate this, we conducted
adoptive transfer experiments where CFSE (green fluorescent dye) labeled Fr.
III leukocytes were intravenously (IV) injected into healthy recipient mice, in
which zymosan peritonitis was subsequently induced. Surprisingly, our study
showed that leukocytes transferred from mice in the recovery phase
demonstrated a 5-fold increase in infiltration when compared to 0d healthy mice
with ~80% of leukocytes arriving in 2.5 hours (Fig. 3.3E). Despite this finding,
immature myeloid leukocyte accumulation in the peritoneum was gradual when
compared to functionally primed mature PMN.
3.3.4 G-MDSC expansion and immunosuppression in colitis-torecovery mice:
Initially, we hypothesized that the immature effector population were a result of
emergency myelopoiesis, as chronic colitis has been shown to induce this
process in the BM. Emergency myelopoiesis is a process where immature
myeloid leukocytes are released from the BM before maturation to replenish the
circulating PMN population

77,223,229 .

However, recent studies have suggested

that under the same conditions a portion of these leukocytes expand in the BM
and differentiate into myeloid derived suppressor cells (MDSC), another type of
myeloid leukocyte. MDSC are comprised of a heterogenous mixture of Ly6C high
monocytes and Ly6G + low - density granulocytes, like what was observed in Fr.
III. MDSC are derived from the same hematopoietic progenitors as PMN
44,99,106,129,223,236 .

Therefore, MDSC can be activated by many of the same
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inflammatory factors as PMN, especially IL-6 and GM-CSF and share many of
the same proteins. Unfortunately, this makes it difficult to phenotypically
distinguish between the two myeloid populations. Despite this, MDSC can be
identified by the gain of two distinct attributes, 1) the ability to enter circulation
before maturation and 2) potent inhibition of T lymphocyte responses
83,97,105,108,117,126,225 .

The most efficient way to determine if the Fr. population are inflammatory PMN
precursors or MDSC is to test for T cell inhibition capabilities. To do this,
splenic T cells from healthy C57BL/6 mice were labeled with CFSE, a green
fluorescent dye with an ester. Once in the cell, the ester on CFSE is cleaved so
that the dye cannot exit the cell, therefore fluorescence will decrease only when
cells proliferate. Following labeling with CFSE, T cell proliferation was induced
by antibody ligation of T cell receptor (TCR) proteins CD3 and CD28. Fr. III
myeloid leukocytes were then added to this system at a 1:6 ratio of leukocytes:
splenocytes. After being cultured for 4d, the decrease of CFSE fluorescence in
the T cells was analyzed by flow cytometry. In Fig. 3.4A, we show that Fr. III
low-density myeloid leukocytes demonstrate potent inhibition of T cell
proliferation at the post-acute stage (9d) with inhibition continuing through
complete inflammation resolution (30d).

Studies suggest that arginase-1 (ARG-1) expression plays an important role in
MDSC suppression of T cells. Specifically, ARG-1 mediated depletion of Larginine from the microenvironment is thought to impede T cell development,
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expansion, and effector functions

76,111-113,116 .

Therefore, upon finding that Fr. III

leukocytes gain immunosuppressive capabilities, we decided to examine ARG-1
expression. Indeed, we show that like our cancer models, ARG-1 expression was
induced in these leukocytes only after coculture with CD3/CD28 activated
splenocytes (Fig. 3.4B). Fr. III leukocytes collected from mice in the post-acute
and recovery stages of treatment (12, 18, and 21d) displayed induction of ARG-1.
As ARG-1 is primarily expressed by M2 macrophages and MDSC, these findings
indicate that these leukocytes are MDSC

20,110 .

Since Fr. III contains a mixture of Ly6C high and Ly6G + leukocytes, magneticactivated cell sorting (MACS) was used to further separate MDSC into the
granulocytic and monocytic subpopulations. Testing these separated populations
revealed monocytes in the BM display inhibition of T cells, even in healthy
animals, suggesting that a percentage of leukocytes may be M-MDSC even at
homeostasis. On the other hand, G-MDSC gained inhibitory functions during the
post-acute stage that lasted throughout inflammation resolution (Fig. 3.4 D).
Despite this, Fig. 3.4 C shows that the expanded population of Fr. III leukocytes
were primarily comprised of Ly6G + CXCR2 high G-MDSC (~41%), that displayed
enhanced infiltration during our adoptive transfer experiments. Taken together,
these data imply that G-MDSC are the primary subset playing a role in DSSinduced colitis.

54

3.3.5 G-MDSC accumulate in the spleens and colons of colitis-torecovery mice.
MDSC are typically associated with tissue repair in healthy individuals and
tumor progression in cancer where they promote an immune-tolerant host
condition

102,103 .

However, the role of MDSC in chronic inflammation is still

under investigation. Spleens of colitis-to-recovery mice were examined to
investigate the role of MDSC in the periphery. Flow cytometric analyses of
myeloid leukocytes in the spleen of recovery mice demonstrated a 5-fold increase
in the percent of Ly6G + granulocytes, recapitulating the expansion that was
observed in the BM (Fig. 3.5A). Expansion of granulocytes during resolution was
tightly correlated with an overall decrease in CD4 and CD8 T cells in the spleen
(Fig. 3.5B). Since PMN infiltrate tissues primarily during chronic inflammation,
it was hypothesized that expanded population were immunosuppressive MDSC.

Since high numbers of granulocytes were found in the spleens of treatment mice,
we postulated that G-MDSC may infiltrate colonic tissues during inflammation
recovery. To test this, histopathological staining of colon tissues from mice at
various stages of treatment was conducted. Indeed, we show that high numbers
of granulocytes were found in murine colons at the post-acute phase. During
inflammation resolution, ARG-1 + Ly6G + cells were identified in colons
displaying tissue repair morphology (Fig. 3.5 C). Furthermore, Ly6G + leukocyte
accumulation in the colon tightly correlated with expression of tissue repair
markers Ki67 (proliferation) and a-smooth muscle actin (a-SMA). Collectively,
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these data suggest that ARG-1 + Ly6G + cells present in the colon during
inflammation resolution are G-MDSC and likely play a role in tissue repair.
3.4 Discussion
PMN were found to display enhanced infiltration and response in multiple
chronic inflammatory models, but particularly during DSS-induced colitis
26,66,178,188 .

Our previous study revealed that enhanced PMN infiltration and

response were a result of changes to the myeloid compartment of the BM during
the post-acute stage of DSS treatment 1 . Despite these findings, there are few
studies investigating the magnitude of PMN alternations in the BM before they
are recruited into circulation. In our studies, PMN numbers were significantly
decreased in the BM of mice with post-acute colitis. Simultaneous extensive
expansion of immature CD11b+Gr1+ myeloid leukocytes was also observed in the
BM of DSS treated mice. These leukocytes were originally thought to be
comprised primarily of PMN precursors. Later, it was found that they instead
resembled MDSCs, which are a heterogeneous population of immature
immunosuppressive monocytes (M-MDSCs) and granulocytes (G-MDSCs)
76,96,105,106,236 .

Clearly, the mechanisms by which chronic inflammatory

conditions and particularly colitis, alter myelopoiesis to induce both proinflammatory and immunosuppressive myeloid leukocytes are complex.
Understanding the role of the expanded population of MDSC in colitis will not
only help to elucidate these mechanisms, but also evaluate their therapeutic
potential in ulcerative colitis.
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In DSS-induced colitis-to-recovery mice, the immature granulocyte populationwhich were later confirmed to be G-MDSCs- significantly expanded in the BM at
the post-acute stage. These cells comprised majority of the expanded CD11b+Gr1+ myeloid leukocyte population. On the other hand, numbers of immature
Ly6Chigh monocytes/M-MDSCs displayed no significant changes throughout
colitis-to-recovery treatment. Although expansion of G-MDSC was associated
with significant decreases in the mature granulocyte (PMN) population, it was
predicted that this was correlative and not causal, as PMN are mobilized in high
numbers from the BM during chronic inflammation. In fact, PMN and more
recently G-MDSC have been identified in the circulation and tissues of patients
with ulcerative colitis

4,25,57,93,95,96,171,237 .

These studies suggest chronic

inflammation induces emergency myelopoiesis in the BM. This conclusion agrees
with various human chronic inflammatory disease studies, in which emergency
myelopoiesis are reported to occur

77,223,229 .

Additionally, this conclusion is in

agreement with the theory that chronic inflammation induced emergency
myelopoiesis produces not only PMN precursors, but also immature myeloid
leukocytes that can expand and differentiate to MDSC after stimulation by serum
cytokines

77 .

The role of MDSC in chronic inflammatory diseases is controversial

as they have been shown to display both pro-inflammatory and
immunosuppressive characteristics in different models of chronic intestinal
inflammation

76,93,102,114,136,142,238 .

The data collected revealed that G-MDSCs induced by chronic inflammation are
distinct from healthy immature granulocytes and mature PMN. MDSC
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demonstrated T cell inhibitory capacity, expression of ARG-1, and increased
expression of CXCR2 when compared to healthy immature granulocytes.
Elevated CXCR2 expression allows G-MDSC to gain egress from the BM and
enter into circulation, which is not the case in healthy conditions where low
expression of CXCR2 restrains immature granulocytes to the BM

12,22,93,235 .

Despite this finding, G-MDSC still shared some characteristics with immature
granulocytes such as, cell density, complexity indicated by SSC value, and nonsegmented nuclei. Thus, G-MDSC resemble true effector cells with the ability to
be released into circulation and perform immunosuppressive functions
elsewhere in the body. PMN and G-MDSC adoptively transferred from
chronically inflamed mice to healthy donor mice both demonstrated enhanced
infiltration during zymosan-induced peritonitis. However, in comparison with
PMN, which accumulated in the peritoneum during the height of post-acute
inflammation, MDSC were found to accumulate, albeit in smaller amounts, late
in the post-acute phase closer to inflammation recovery. These results not only
indicate that PMN become functionally primed in the BM of chronically inflamed
mice, but that G-MDSC may infiltrate the colon during tissue repair. Indeed,
PMN infiltration of the colon is required for clearance of commensal bacteria
that can act as a driving force of colitis, but the deleterious effects caused by
their enhanced responses greatly promote colitis pathology as well

4,6,25,47,51,68 .

Therefore, it is plausible that the chronically inflamed microenvironment
releases signals to alter myelopoiesis and produce immunosuppressive
granulocytes to balance the effects of PMN and other pro-inflammatory cell
types including CD4 and CD8 T lymphocytes, so that all the processes required
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to initiate inflammation resolution can occur. Reports by Su et al., and Guan et
al., demonstrated that adoptive transfer of MDSC to mice with intestinal
inflammation resulted in decreased IFN-γ, TNF-α, IL-17, IL-6 expression, and
myeloperoxidase activity in the colonic mucosa, all of which have been found to
contribute to leukocyte recruitment, activation, and effector functions

138,140 .

If

this is the case, induction of G-MDSC could be a therapeutic treatment option
for patients with chronic inflammation.

To determine the therapeutic potential of MDSC, their role in chronic
inflammation must be elucidated. Studies show that in experiments where
MDSCs were adoptively transferred to in vivo models of rheumatoid arthritis
(RA) and experimental autoimmune encephalomyelitis (EAE) they alleviated
symptoms associated with each disease. A protective role of MDSC in allogeneic
transplantation has also been documented

136-138,142,238 .

In our study, expansion

of G-MDSC in the spleens of DSS-induced colitis-to-recovery mice corroborated
these findings, as it was accompanied by an overall decrease in splenic CD3+ T
cells. This suggest that MDSC in the spleens of colitis mice inhibit the
proliferation of T splenocytes, disrupting their recruitment into the inflamed
colonic mucosa. Continuous infiltration of leukocytes, especially PMN and T
lymphocytes, have been shown to promote colitis pathology

3,10,14,15,36,43,74,219 .

Furthermore, ARG-1 expressing Ly6G+ granulocytes were observed in the colons
of mice during inflammation recovery. This was tightly correlated with increased
expression of Ki-67 and a-SMA, which are cell proliferation and repair proteins
that are generally elevated during tissue remodeling under chronic inflammatory
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conditions

239,240 .

In accordance with this, a study conducted by Zhang et al.,

revealed that MDSCs transferred to colitis mice reduced inflammation and more
importantly facilitated colonic mucosal healing. MDSC have also been reported
to contribute to tissue repair in healthy individuals

102,139,234,241 .

Despite this

evidence the role of MDSC remains controversial, as some studies have shown
that G-MDSC- like cells in the colon of mice with colitis gained APC functions,
induced T cell activation and pro-inflammatory cytokine production

54,96 .

Based

on these data, it is reasonable to conclude that suppression of leukocyte
infiltration and responses by G-MDSC facilitates inflammation resolution,
thereby promoting colon tissue repair.

Although these results provide crucial insight about the changes that occur to
the myeloid compartment under chronic inflammatory conditions, the factor(s)
that induce these alterations are still under investigation. IL-17 is highly
expressed in the serum and colonic mucosa of ulcerative colitis patients
1,63,149,154,155,165 .

Specifically, elevated expression of IL-17 has been shown to

perpetuate chronic colitis through regulation of PMN differentiation, activation,
and recruitment from the BM. Despite this observation, attempts to neutralize
IL-17 with antibodies in ulcerative colitis patients were unsuccessful but resulted
in exacerbation of the disease

155,159,161-164,166,169 .

Exacerbation of colitis symptoms in IL-17 neutralized patients indicated that IL17 plays a more complex role in colitis than originally thought. Research
investigating this phenomenon suggest that the exacerbated colitis pathology

60

induced by inhibition of IL-7 expression could be attributed to increased
invasion of commensal bacteria as a result of impaired PMN infiltration and
response. Additionally, IL-17, in conjunction with IL-22, was found to help
maintain tight epithelial junctions and promote epithelial cell regeneration in
the intestine. Therefore, IL-17s inhibition in colitis models could also contribute
to disease exacerbation in a similar mechanism

143,144,149 .

In our study, IL-17 was

still elevated in the serum of DSS-induced colitis-to-recovery mice, albeit at
lower levels, during inflammation resolution when expansion of G-MDSC was
observed. Considering these findings, it is also plausible that inhibition of IL-17
may have blocked MDSC expansion, thereby removing the immunosuppressive
leukocytes that may help to balance inflammatory responses in the colon.
However, IL-17s role in the development of MDSC has yet to be studied in
chronic colitis. IL-17 is known to induce factors needed for PMN regulation,
especially IL-6 and GM-CSF, which have also been found to induce MDSC under
disease conditions. It has also been shown to induce production of other myeloid
leukocyte stimulatory factors associated with MDSC expansion such as G-CSF,
IL-4, and Il-10

95,116,138,142,225 .

Most studies suggest at least two or more cytokines

from the aforementioned factors are required for induction of MDSC during
chronic inflammation. Since, IL-17 has been found to induce secretion of these
factors by various cells subsets in the intestine, such as epithelial cells, it can be
hypothesized that it may act as an upstream master regulator of MDSC
development. Recent studies utilizing in vivo models of colorectal cancer and
Lewis lung carcinoma provide evidence that IL-17 not only promotes expansion
of MDSC, but also inhibits their apoptosis in the tumor microenvironment

226,227 .
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Figure 3.1. An active inflammation-recovery mouse model.
A) Scheme of DSS-induced colitis–recovery model in C57BL/6 mice. Mice ~20g were treated with 2% DSS
in drinking water for 9 d, followed by 21 d of pure water to allow for recovery. Indicators of disease
progression and recovery were monitored. B) Percent body weight loss for colitis-recovery and control
mice. C) Disease activity index score (DAI). Body weight loss, stool consistency, and bloody stool were
scored on a scale of 1-3 and averaged. n = 5 D) Assessment of colon tissue damage by measuring colon
length. E) Pro-inflammatory cytokine (IL-17, IL-6, IFN-γ and GM-CSF) expression in the serum of DSScolitis mice were assayed using ELISA. F) Measurement of fecal lipocalin-2 (LCN-2) by ELISA for colitisto-recovery mice. Data are represented as median ± SEM. Significant differences were determined by
student T test * p ≤ 0.05, ** p ≤ 0.001, *** p ≤ 0.0001 versus respective controls.
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Figure 3.2. Percoll separation of bone marrow leukocytes.
A) BM harvested from healthy and DSS-recovery mice were applied to discontinuous Percoll density
gradients and centrifuged. Four cell-enriched fractions (Fr. I, II, III, and IV) were formed at sequentially
increased density interfaces (70, 60, 50, 40, and 5%). B) FACS analysis of CD11b+, Ly6Chigh and Ly6G+
BM leukocytes. C) Analyses Ly6G+ granulocytes in Fr. III & IV for FSC and SSC values. D) Progressive
expansion of Fr. III Ly6G+ granulocytes in mice under colitis-to-recovery treatment. Graph is expressed
as median ± SEM. Significant differences were determined by student T test * p < 0.05, ** p < 0.01, *** p
< 0.001 versus respective controls. These data represents > five independent experiments with three mice
per experiment.
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Table 3-1. Dynamic changes in the myeloid compartment during DSS-induced colitisrecovery.
Leukocytes from colitis-to-recovery mice were harvested from femur and tibia bones, this
was followed by Percoll gradient separation. Total BM cells prior to separation and cells
distributed in Fr. I to IV were counted. Ly6Chigh and Ly6G+ cells in Fr. III were determined
by FACS. The significant differences between the tested groups were calculated by one-way
ANOVA followed by Dunnett’s Multiple Comparison test. a) p 0.001
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Figure 3.3. Functional alteration of the myeloid compartment.
A) PMA-induced ROS production in mature PMN determined by DCFDA
staining. B) In vivo granulocyte trafficking to peritoneum. Isolated Fr. IV
mature PMN from colitis-to-recovery mice were labeled with fluorescence dye
CMTMR (red). Red leukocytes from Fr. IV were then transferred into healthy
recipients. Following this, to induce PMN infiltration mice were immediately
injected with zymosan. At 2.5 hr post-injection the contents of the peritoneal
cavity were collected and analyzed for colored granulocytes within
CD11b+Ly6G+ cells. C) FACS analysis of CXCR2 surface expression on Fr. III
Ly6Chigh and Ly6G+ BM leukocytes. D) PMA-induced ROS production in Fr. III
Ly6Chigh and Ly6G+ leukocytes, determined by DCFDA staining. E) Isolated Fr.
III Ly6Chigh and Ly6G+ granulocytes from colitis-to-recovery mice were labeled
with fluorescence dye, CFSE (green). Green granulocytes of Fr. III were then
transferred into healthy recipients. Following this, zymosan peritonitis was
induced for 2.5 hr. All graph data is expressed as median ± SEM, Significant
differences for (A,B,C) were determined by student T test, and one- way ANOVA
(D,E) * p < 0.05, ** p < 0.01, *** p < 0.001 versus respective controls
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Figure 3.4. G-MDSC expansion and immunosuppression.
A) Assay for Fr. III leukocyte mediated inhibition of T-cell proliferation. Splenic
T cells labeled with CFSE were induced to proliferate by antibody ligations of
CD3 and CD28 (CD3/CD28) in the absence (control) or the presence of Fr. III
myeloid leukocytes at a ratio of 1:8 leukocytes: splenocytes. After 4 days (4d),
the proliferation of T cells, both CD4 and CD8, was determined by flow
cytometric analyses of CSFE dilution (left shift). NC, no proliferation induction.
B) Western blot detecting arginase-1 in band III BM leukocytes before (-) and
after (+) co-culturing these cells with T cells proliferation media. C) Analysis of
Fr. III Ly6C high and Ly6G+ cell numbers in treatment mice D) Inhibitory effect
of M-MDSC and G-MDSC on T-cell proliferation. Fr. III MDSC were further
separated into M-MDSC and G-MDSC by Ly6C and Ly6G selection, respectively,
prior to testing in T-cell proliferation assays. The MDSC: splenocytes = 1:6.
Significant differences (C) analyzed by student T test * p < 0.05, ** p < 0.01, ***
p < 0.001 versus respective controls.
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Figure 3.5. G-MDSC accumulate in the spleens and colons of colitis-to-recovery mice.
A) Expansion of Ly6Chigh and Ly6G+ myeloid leukocytes in the spleens of recovery
mice determined by FACS. B) FACS analysis of CD4 and CD8 T splenocytes in mice
throughout colitis-to-recovery treatment. C) H&E and Immunofluorescent staining for
Ly6G, Ki67, and a-SMA in colons from mice under DSS-induced colitis-to-recovery
treatment. All graph data is expressed as median ± SEM, Significant differences were
determined by one-way ANOVA *p < 0.05, ** p < 0.01, *** p < 0.001
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4

CONCLUSIONS

The concepts reviewed in this dissertation coupled with our findings have led to
several conclusions. Specifically, my data suggest that when a healthy mouse
becomes chronically inflamed, systemically elevated IL -17 induces a
reprograming event in the myeloid compartment of the bone marrow (BM).
Based on the research available, I believe that IL-17 may induce secretion of
myeloid leukocyte stimulatory factors to indirectly act on PMN and MDSC. The
literature shows that IL-17 is induces release of IL-6 and GM-CSF by fibroblast
and stromal cells in the BM

81,145,149,154,159,242 .

Elevated expression IL-6 and GM-

CSF in the BM has been found to activate transcription factors, including NF-κB,
P38/MAPK, C/EBPβ and SOCS3, that initiate emergency myelopoiesis. A major
outcome of emergency myelopoiesis is the production of altered subsets of
myeloid leukocytes

77,221-223,229 .

Although studies have investigated how myeloid

leukocytes produced by emergency myelopoiesis are altered in the tissues,
research on these subsets in the BM is not as common.

Analyzing the BM of DSS-induced colitis-to-recovery mice recapitulated findings
that the myeloid compartment is altered under chronic inflammatory conditions
1,203 .

Indeed, my work shows that both immature and mature myeloid leukocyte

population sizes changes dynamically throughout treatment. The mature PMN
subset steadily decreased during the post-acute phase of treatment. Despite
decreases in numbers, PMN displayed enhanced infiltration and responses. In
fact, PMN infiltration and ROS production was at its highest when their
numbers in the BM were at their lowest (9d). This suggest that PMN are
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functionally primed early in chronic inflammation in preparation for mass
recruitment from the BM.

Surprisingly, the immature myeloid leukocyte population rapidly expanded
during chronic colitis. Unlike PMN, peak immature myeloid leukocyte expansion
occurred at 12d in the BM. This was coupled with increased expression of CXCR,
ROS production, and infiltration. Immature leukocytes remained altered until
the end of resolution ~30d. Increased migratory capabilities and pathogen
removal abilities beginning in late stage post-acute inflammation indicate that
these leukocytes migrate into the inflamed mucosa toward the end of
inflammation.

In acute inflammation, PMN are thought to be primed in circulation and during
transmigration into the inflamed area so that they can infiltrate the tissue and
rapidly preform their functions

4-6 .

Our study suggests that when the condition

becomes chronic, similar to what was observed in our post-acute colitis mice,
functional priming of PMN occurs in the BM and this contributes to the
enhanced infiltration and response we see under ulcerative colitis conditions.
Therefore, these enhanced inflammatory leukocytes are likely a consequence of
continuous pro-inflammatory signals being sent in the serum from the
unresolved intestinal microenvironment. Functionally altered PMN may develop
as a mechanism to deal with the unresolved insult, but it is more likely that
under these conditions they significantly contribute tissue damage in the colon
as well.
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Significant expansion of immature granulocytes, identified to be G-MDSC by
expression of ARG-1 and potent suppression of T cell proliferation, were also
observed during post-acute inflammation. G-MDSCs displayed increased
expression of CXCR2, which indicated gain of migratory capabilities that are not
demonstrated by healthy immature granulocytes. Indeed, immunofluorescent
staining of colitis-to-recovery colons revealed that G-MDSC accumulate in the
colon of DSS treated mice during post-acute inflammation and resolution.
Additionally, the presence of granulocytes in spleens of these mice tightly
correlated with decreases in splenic CD3+ CD4 and CD8 T cells.

While the role of G-MDSC in chronic colitis is still under investigation, based on
their presence in the colon and potent inhibition of T cells in ex vivo assays, we
hypothesize that MDSC suppress the responses of leukocytes, especially T cells
in the inflamed colon. MDSC have been associated with tissue repair in several
studies, including ours where we show high expression of tissue repair markers
Ki-67 and a-SMA when G-MDSC are present in the colon. MDSC have also been
shown to suppress multiple other pro-inflammatory leukocytes and induce
immunosuppressive cell types such as T regulatory cells (Treg) and M2
macrophages

83,87,95,130,131,225 .

Collectively, these studies suggest that G-MDSCs

impair the responses of leukocytes, including T cells, PMN, and M1 macrophages
to counteract the effects of their exacerbated response in the inflamed colonic
mucosa, thereby promoting inflammation resolution.
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Figure 4.1: Altered myelopoiesis in the bone marrow of colitis mice.
Schematic depiction of the reprogramming that occurs in the myeloid
compartment of the BM during chronic inflammation.
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